Monday, October 5, 2026

ARM Targets $15B Annual Revenue with First Data Center Chips, Abandoning Pure IP Licensing Model

ARM Holdings will design and sell its own data center processors for the first time, projecting $15 billion in annual revenue within five years as AI infrastructure demands reshape semiconductor business models. The ARM AGI CPU claims 2x performance per rack versus x86 platforms, marking a shift from licensing intellectual property to competing directly in silicon manufacturing.

LM Salvado

March 28, 2026

ARM Targets $15B Annual Revenue with First Data Center Chips, Abandoning Pure IP Licensing Model
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ARM Holdings plans to generate $15 billion in annual revenue within five years from a new data center chip business, according to CEO Rene Haas.1 The move abandons the company's decades-old model of licensing processor designs to chipmakers without manufacturing competing products.

The ARM AGI CPU delivers more than 2x performance per rack compared with x86 platforms, ARM states.2 Partners are requesting deployment of ARM technology at scale as AI transforms computing infrastructure, driving the strategic pivot.2

The shift reflects broader changes in semiconductor value capture. IP licensing alone no longer captures the economic value created by AI workloads, pushing ARM to vertical integration. This mirrors trends across the chip ecosystem where companies are expanding beyond traditional boundaries.

Arteris expanded AI-chip interconnect capabilities with FlexGen technology, enabling teams to generate optimized interconnects with improved power, performance, and area results.3 The network-on-chip IP addresses bottlenecks in AI processor architectures where data movement between cores increasingly limits performance.

FormFactor advanced silicon photonics testing for AI data centers, where optical interconnects are replacing copper to handle bandwidth demands.4 The technology addresses heat and power constraints in dense compute environments running large language models.

Wolfspeed refinanced debt to lower annual interest expense by $62 million, preserving capital for silicon carbide production.5 The wide-bandgap semiconductors enable power efficiency in AI server infrastructure.

ARM's entry into silicon sales creates direct competition with licensees including Amazon, Microsoft, and Google who design custom ARM-based server processors. The $15 billion revenue target represents roughly 30% of the current data center processor market, indicating ARM expects substantial displacement of existing architectures.

The transformation occurs as geopolitical factors reshape semiconductor supply chains, with US rare earth export restrictions to China forcing diversification of material sources for chip production. AI infrastructure buildout is accelerating these structural changes across the industry.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· March 24, 2026
    Arm Expands Compute Platform to Silicon Products in Historic Company First
  2. [2]News articleYahoo Finance· March 25, 2026
    Arteris Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
  3. [3]News articleYahoo Finance· March 25, 2026
    FormFactor and Copart have been highlighted as Zacks Bull and Bear of the Day
  4. [4]News articleNasdaq· March 25, 2026
    Stocks Climb on Hopes of US-Iran Diplomacy
  5. [5]News articleNasdaq· March 25, 2026
    Stocks Finish Higher on US Push to End Iran War
  6. [6]News articleNasdaq· March 25, 2026
    Stocks Rally on US Peace Plan to End Iran War
  7. [7]News articleYahoo Finance· March 26, 2026
    Strategic Refinancing and New Equity Issuance Support Wolfspeed’s Long-term Growth Potential
  8. [8]News articleYahoo Finance· March 25, 2026
    Universal Display to Highlight OLED Emissive Layer Advances for Display Efficiency and Performance at ICDT 2026
  9. [9]News articleNasdaq· March 26, 2026
    Zacks Investment Ideas feature highlights: Arm Holdings, NVIDIA, Advanced Micro Devices, Apple, Qualcomm and Meta Platforms
  10. [10]News articleYahoo Finance· November 26, 2025
    AI to Reshape the Global Technology Landscape in 2026, Says TrendForce
  11. [11]News articleYahoo Finance· March 19, 2026
    A New U.S. Facility Could Break China’s Grip on Critical Materials
  12. [12]News articleYahoo Finance· March 25, 2026
    Here's How Micron Technology, Nvidia, and AMD Could Help This Unstoppable ETF Turn $250,000 Into $1 Million in 10 Years

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com